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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a severe liver disease that is increasing in prevalence with the worldwide epidemic of obesity
and its related insulin-resistance state. A ‘two-hit’ mechanism has been proposed; however, the complete physiopathogenesis remains
incompletely understood. Evidence for the role of the gut microbiota in energy storage and the subsequent development of obesity and
some of its related diseases is now well established. More recently, a new role of gut microbiota has emerged in NAFLD. The gut microbiota
is involved in gut permeability, low-grade inﬂammation and immune balance, it modulates dietary choline metabolism, regulates bile acid
metabolism and produces endogenous ethanol. All of these factors are molecular mechanisms by which the microbiota can induce NAFLD
or its progression toward overt non-alcoholic steatohepatitis.
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Introduction
The epidemic of obesity [1,2] has led to the dramatic increase
of its related metabolic diseases, namely insulin resistance, type
2 diabetes and non-alcoholic fatty liver disease (NAFLD) [3].
The mechanisms involved in weight gain and the development
of obesity are numerous and complex, and research continues
to uncover new factors. In the past few years, a potential role
of the gut microbiota has emerged in weight regulation [4–8].
The gut microbiota is now considered as a major metabolic
internal organ, composed of >1014 microorganisms and
containing a second genome (named the metagenome), which
is up to 100–400 times that of humans [9]. Culture-indepen-
dent, large-scale tools [10] and associated projects such as the
Human Microbiome Project [11] or the MetaHit consortium
[9] have enabled major breakthroughs in the understanding of
gut microbiota composition and functions in different patho-
logical conditions. Data suggest an important impact of the gut
microbiota on health [12] and in the pathogenesis of certain
inﬂammatory and metabolic [13] diseases such as type 2
diabetes [14] and obesity. Recent literature also points to a
potential role in the development of NAFLD.
Non-alcoholic fatty liver disease is a very prevalent and
severe disease that can lead to cirrhosis, liver carcinoma [15] and
death related to liver morbidity. In addition, data show that
NAFLD correlates with increased cardiovascular risk assess-
ment scores andmost of the clinical surrogates of cardiovascular
diseases. A few smaller studies have suggested that NAFLD
induces not only increased risk of patent cardiovascular disease,
independently of usual risk factors [16,17] and of other
components of metabolic syndrome, but also increased risk of
related mortality [18,19]. However, no treatment has yet
proven effective to improve non-alcoholic steatohepatitis
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(NASH) [20,21]. Finding novel mechanisms for the pathogenesis
ofNASH, in particular involving themicrobiota, could emphasize
new research areas to develop new therapeutic targets.
This review summarizes what is currently known of
microbiota composition in obesity and the physiopathogenesis
of NAFLD in that context. Recent literature suggests a role of
the gut microbiota in NAFLD but mainly in animal models. We
therefore aim to present the putative molecular mechanisms
linking fatty liver and gut microﬂora.
NAFLD and Obesity
Non-alcoholic fatty liver disease is a frequent disease, occurring
in 16–30% of the general population, depending on the
assessment method [22,23]. Its prevalence rises [24] in parallel
with the worldwide epidemic of obesity and metabolic diseases
[25], reaching 50–90% of obese individuals, among whom more
than one-third present with overt NASH [26]. The diagnosis of
NAFLD is made on histological ﬁndings, ﬁrst described by
Kleiner and Brunt and their colleagues [27,28]. It includes a wide
spectrum of lesions, starting with steatosis, characterized by the
accumulation of triglycerides within the hepatocytes [29], in the
absence of other liver disease or signiﬁcant alcohol consump-
tion [21]. Some patients will also develop hepatocyte injuries,
such as ballooning and inﬂammatory inﬁltrates, both responsible
for NASH, with or without concomitant collagen deposition
(ﬁbrosis) that potentially leads to end-stage cirrhosis [30].
Recently, a new algorithm also based upon histological deter-
mination has been proposed and validated to better deﬁne early
stages of NASH, most particularly in morbidly obese patients
[31]. Although liver biopsy is the gold standard to conﬁrm the
diagnosis, it is an invasive and costly procedure, potentially
responsible for secondary effects [32,33]. Furthermore, con-
sidering the ever-increasing prevalence of both diabetes [34]
and obesity [35], and the subsequent number of patients at risk
for liver alterations, it cannot be considered a practical, efﬁcient
and large-scale tool to identify those at risk of NASH or
advanced ﬁbrosis. In that context, a clinical scoring system
including type 2 diabetes, hypertension, sleep apnea and
ethnicity has been suggested to propose liver biopsy for those
at high risk of NASH [36]. Other imaging techniques include fast
magnetic resonance imaging [37], computed tomography,
ultrasound [38] and emerging proton magnetic resonance
spectroscopy, which is a reliable non-invasive tool to quantify
hepatic triglyceride content [39]. The last of these correlates
closely with histopathological grade [40] and allows larger
sampling than liver biopsy (8–27 cm3). Recently, non-invasive
tests, initially used in viral hepatitis B [41] and C [42], have been
developed, that are currently validated to screen NAFLD in at-
risk populations. For example, Fibromax, which is an algorithm
including an association of gender, age, weight, height and
numerous serum biomarkers, has shown good reliability in the
prediction of liver abnormalities including steatosis [43], NASH
[44] and ﬁbrosis, in both overweight patients and in those at
different stages of obesity [45–47].
Regarding the pathogenesis of NAFLD, for a long time, a
‘two-hit’ mechanism was proposed to explain the progression
in liver alteration stages, where the ﬁrst hit consists in
hepatocyte lipid accumulation mainly due to obesity and insulin
resistance [48]. Then a second hit, occurring in some patients
only, plays a role in the shift from steatosis to NASH [49,50].
Several factors have been incriminated in the pathophysiology
of NAFLD such as oxidative stress, systemic inﬂammatory
mediators and chronic intermittent hypoxia [51–53]. Further-
more, adipose tissue inﬂammatory tone [54] also seems to
play an important role, because patients with more severe
stages of NASH display increased macrophage accumulation in
visceral adipose tissue [55]. Moreover, their deep subcutane-
ous adipose tissue not only displays increased macrophage
inﬁltration but also increased inﬂammatory gene expression
compared with superﬁcial adipose tissue [56]. These associ-
ations between macrophage accumulation in adipose tissue
and NASH stages were found independently of the diabetes
status in morbid obesity.
More recently, an alternative theory favours the determi-
nant effect of free fatty acid lipotoxicity in liver injury, which
leads to NASH and occurs in parallel with triglyceride droplet
accumulation (i.e. steatosis) [57]. Hepatic steatosis is known to
develop in the context of an imbalance of triglycerides afﬂux in
the liver, which is dramatically increased during obesity and
even more so when associated with insulin resistance. Indeed
in that context, there is a concomitant increased supply
(coming from diet, de novo lipogenesis [58] and adipose tissue)
and decreased degradation (via impaired b-oxidation) [57]. A
special focus should be placed on fructose consumption, which
is dramatically increased in the western diet [59]. Indeed, its
metabolism induces both de novo hepatic lipogenesis and
reactive oxygen species (ROS) production and therefore
participates in the two ‘hits’ of NAFLD physiopathology [60].
Yet to date, the complete pathogenesis of NAFLD is still
unknown and many more factors remain still to be uncovered,
in particular the precise role of gut microbiota.
Microbiota Composition in Obesity
Studies in mice indicated a relation between gut microbiota
and weight regulation. Indeed, germ-free mice displayed
reduced adiposity despite increased food consumption when
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compared with conventional animals. Most importantly, colo-
nization with caecal content from conventional mice induced a
rapid fat mass gain, even though those mice ingested less food
[4,61,62]. The physiopathogenesis by which microbiota plays a
role in obesity development was ﬁnally conﬁrmed after
manipulation in mice and implies multiple mechanisms. The
gut microbiota is able to process otherwise indigestible dietary
polysaccharides [62–64] into short-chain fatty acids [65] that
can subsequently be absorbed by the intestine. Moreover, the
microbiota directly impacts gene regulation to favour
increased storage into adipose tissue [4]. Finally, experiments
comparing the feces of obese and lean individuals demon-
strated that the level of short-chain fatty acids was higher in
the obese whereas residual calories from food were concom-
itantly reduced. These results suggested that the microbiota
from obese animals displayed increased capacity to extract and
subsequently store energy compared with that of lean animals
[65,66]. Since then, studies in mice using 16S rRNA sequencing
methods have demonstrated that microbiota composition
differs in obese and lean individuals, with increased Firmicutes
and decreased Bacteroidetes levels in the obese although they
ingested the same amount of food [67]. The same result was
also found in a small study in humans, where obese individuals
also displayed increased Firmicutes and decreased Bacteroi-
detes compared with lean ones [68], data that were later
conﬁrmed in larger cohorts [69,70]. However, this result
remains under debate because conﬂicting data have also
emerged [66,71,72]. Indeed, using two techniques, Duncan
et al. observed no differences in the numbers of Bacteroidetes
in obese or lean patients [71,72]. Likewise, Jumpertz et al.
found the same level of the three dominant phyla (namely
Bacteroidetes, Fimicutes and Actinobacteria) in groups with
different body mass index [73].
Those discrepancies have led to further studies, using large-
scale metagenomic tools that enabled interesting discoveries:
First, recent data in humans have focused on the importance of
bacterial diversity rather than the composition in different
phyla [74]. Interestingly, in obese populations with a high
prevalence of obesity-related disease, the overall number of
gut microbiota was reduced. This is in line with previous
results in mouse models [61] and humans [69], where greater
corpulence was associated with reduced diversity. Likewise,
children from rural Africa displayed increased microbiota
richness and biodiversity than same-age healthy children from
Western Europe [75].
Second, although gut microbiota display large inter-individual
variability, a ‘core’ microbiota was pointed out since 40% of
the genes from each individual were shared with at least half of
the individuals in the cohort [76]. Most importantly, based on
studies of the microbiome in different large groups of patients,
three Enterotypes, which can be compared with blood types,
have been identiﬁed, that are not driven by corpulence. These
Enterotypes differ according to the abundance of the three
dominant genera, each of them able to process certain types of
nutrients [77]. Indeed, Enterotype 1, enriched in Bacteroides
spp., has been associated with long-term consumption of
animal proteins and saturated fat whereas Enterotype 2
(dominated by Prevotella spp.) is associated with a carbohy-
drate-based diet [78]. Gut microbiota composition seems to
have a strong link with long-term food habits in adults [78].
Moreover, comparison between the microbiota from children
in Western Europe and in rural Africa revealed that the latter
had low levels of Firmicutes and increased levels of Bacter-
oidetes in a link with major food consumption differences,
namely high amounts of plant polysaccharides [75]. Other
aspects of the diet have also been related to the microbiota.
Indeed, the overall increase in calorie content induced a
concomitant rapid increase in numbers of Firmicutes and a
decrease in Bacteroidetes in lean and obese humans [73].
Likewise, when submitted to a high-fat [79,80] or western
[61,81] diet, both mouse and humanized mouse models
displayed the same changes. Finally, Ravussin et al. suggested
that the increase in fat content rather than weight modiﬁca-
tions drove the increase in numbers of Firmicutes [82]. If those
studies demonstrate the unquestionable effect of acute
changes in the diet on the rapid changes in microbiota
composition, it does not translate in to a switch from one
Enterotype to the other [78].
NAFLD and Microbiota
Several lines of evidence suggest a strong interaction between
gut ﬂora and liver. Deriving from its anatomical position, the
liver receives 70% of its blood supply from the intestine through
the portal vein, so it represents the ﬁrst line of defence against
gut-derived antigens, and one of the most exposed organs to
gut-derived toxic factors, such as bacteria and bacterial by-
products [83]. The link between gut microbiota and the
development of NAFLD has been shown in mice and in humans.
In mice, B€ackhed et al. observed that the transplantation of
normal caecal microbiota to germ-free mice induced, 15 days
later, a 60% increase in body fat along with a more than two-fold
increase in hepatic triglyceride content [4]. In the early 1980s, a
parallel development of NASH and small intestinal bacterial
overgrowth was reported in humans after intestinal bypass.
Interestingly, hepatic steatosis regressed after antibiotic treat-
ment (namely metronidazole) [84], suggesting a possible
causative role for microbiota in NAFLD.
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Gut microﬂora may stimulate hepatic fat deposition and
promote NASH though several mechanisms (Fig. 1):
1. It promotes obesity by improving energy yield from food
(see Microbiota and Obesity)
2. It regulates gut permeability, low-grade inﬂammation and
immune balance
3. It modulates dietary choline metabolism
4. It regulates bile acid metabolism
5. It increases endogenous ethanol production by bacteria
Lipopolysaccharide and Toll-like-receptor 4 signalling
NAFLD and other insulin-resistant states are associated with
activation of the innate immune system. The gut microbiota
participate in the development and homeostasis of the overall
immunity of the host [85]. Indeed, the cross-talk between host
and bacteria at the mucosal interface is responsible for innate
and adaptive immune responses that protect the host and
maintain intestinal homeostasis. This depends on speciﬁc
pattern recognition receptors, including Toll-like receptors
(TLRs) and NOD-like receptors that recognize highly con-
served microbial molecules called ‘pathogen-associated molec-
ular patterns’ (PAMPs), whereas the endogenous products are
distinguished in damage-associated molecular patterns
(DAMPs) [83,86,87]. The TLRs, acting as immune sensors of
PAMPs and DAMPs, initiate an adaptive immune response and
a signalling cascade leading to activation of pro-inﬂammatory
genes, such as tumour necrosis factor-a (TNF-a), interleukin-6
(IL-6), IL-8, IL-12 [87]. The most studied PAMP is the
lipopolysaccharide (LPS), a component of the gram-negative
bacteria cell membrane, the active component of endotoxin.
The latter binds to lipopolysaccharide-binding protein (LBP),
which subsequently binds to CD14. The LPS–LBP–CD14
complex activates TLR-4, present in Kupffer cells, triggering an
essential inﬂammatory cascade, including stress-activated and
mitogen-activated protein kinases, Jun N-terminal kinase, p38,
interferon regulatory factor 3 and nuclear factor-jB pathway
[88,89]. Translocation of nuclear factor-jB to the nucleus
induces the transcription of numerous pro-inﬂammatory genes
such as TNF-a and IL-1b [90]. Other bacterial endotoxins such
as peptidoglycan also contribute to stimulate pro-inﬂammatory
cascades though activation of the NOD1 receptor [91]. Many
studies, mostly carried out in animal models, enabled LPS–
TLR-4 signalling activation to be related to insulin-resistance
and NASH. Cani et al., ﬁrst described how a 4-week high-fat
diet led to a moderate increase in plasma LPS concentration in
mice, deﬁning this effect as ‘metabolic endotoxaemia’, because
this increase was still 10–50 times lower than values that could
FIG. 1. Molecular mechanism involved in non-alcoholic fatty liver disease (NAFLD) development and progression: In yellow are the mechanisms
involved in steatosis formation via increased hepatic triglyceride content. In red are the mechanisms involved in the progression from steatosis to
NASH. In grey are the consequences of intestinal dysbiosis. Abbreviations: DAMP, damage-associated molecular pattern; FFA, free fatty acids; FXR,
farnesoid X receptor; IL-6, interleukin-6; LPS, lipopolysaccharide; NASH, non-alcoholic steatohepatitis; PAMP, pathogen-associated molecular
pattern; SCFA, schort-chain fatty acids; SIBO, small intestinal bacterial overgrowth; Tg, triglycerides; TGF-b, transforming growth factor-b; TLR4,
Toll-like receptor 4; TNF-a, tumour necrosis factor-a.
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be reached during septicaemia [80,92]. Importantly, 4 weeks
of continuous infusion of LPS in mice mimicked the high-fat
diet phenotype, namely an increase in insulin resistance, liver
triglyceride content and adipose tissue inﬂammation. Besides,
they demonstrated that these effects were CD14-dependent,
because the phenotype was signiﬁcantly reversed in CD14
knockout mice [80]. The role of the gut microbiota was
further demonstrated by antibiotic treatment reducing the
intensity of the disease in high-fat diet and ob/ob mice [93–95].
Since then, other studies in TLR-4 null mice (–/–) have
conﬁrmed that TLR-4 is essential for hepatic fat deposition and
NASH development [96–98]. Hepatic stellate cells might also
have an important role in generating the liver inﬂammatory
cascade linked with endotoxinaemia. Indeed, they have been
shown to be the target through which TLR-4 promote
ﬁbrogenesis via enhancement of transforming growth factor-
b (TGF-b) signalling [99,100].
Another important contributor to microbiota dysbiosis,
participating in the activation of lipid peroxidation and ROS
production—both involved in the second-hit mechanism in
NAFLD/NASH progression—is the inﬂammasome. Inﬂamma-
somes are cytoplasmic multi-protein complexes composed of
leucin-rich-repeat containing proteins and nucleotide-binding
domain (NLRPs) [101,102], which are sensors of PAMPs and
DAMPs. They govern cleavage of pro-inﬂammatory cytokines
such as IL-1b and pro-IL-18. Most DAMPs induce ROS
production, which is known to activate the NLRP3 inﬂam-
masome [103]. Recently, Henao-Mejia et al., showed that
changes in gut microbiota associated with NLRP6 and
NLRP3 inﬂammasome deﬁciency were linked with exacer-
bated hepatic steatosis and enhanced TNF-a expression.
Furthermore, co-housing inﬂammasome-deﬁcient mice with
wild-type mice transferred the phenotype, providing direct
evidence that inﬂammasome-mediated dysbiosis is implicated
in NASH progression [104]. Studies in humans have
demonstrated increased endotoxin levels in adults and
children with NASH [105–107]. Furthermore, several studies
showed that endotoxin levels increased with the severity of
the disease [108,109]. Likewise, chronic endotoxinemia,
which behaves as a real ‘hepatotoxin’, may be of particular
importance in inducing hepatic inﬂammation, ﬁbrosis and
insulin resistance.
Alteration of intestinal permeability (leaky gut) and small
intestinal bacterial overgrowth
The gut epithelium plays a central role in demarcating
microbes in the gut from the host immune system. Gut
epithelial cells are linked to one another with tight junctions,
which play a pivotal role in maintaining intestinal barrier
integrity [110]. NAFLD and steatohepatitis have been associ-
ated with small intestinal bacterial overgrowth and increased
intestinal permeability [4,111]. Miele et al., provided the ﬁrst
evidence of an increased intestinal permeability (leaky gut) and
tight junction alterations in 35 patients with biopsy-proven
NAFLD compared with healthy subjects. Furthermore, both
gut permeability and the prevalence of small intestinal bacterial
overgrowth correlated with the severity of steatosis, although
not with the presence of NASH [112]. Wigg et al. found small
intestinal bacterial overgrowth in 50% of patients with NASH,
compared with 22% in controls [113]; More recently, G€abele
and co-authors have presented novel experimental evidence
about the association between impaired intestinal barrier
function and hepatic ﬁbrogenesis and inﬂammation [114]. The
authors induced NASH by feeding C57BL/6 mice with a high-
fat diet and then studied the effects of exposing the mice to 1%
dextran sulphate sodium. Such exposure led to intestinal
epithelial injury. Importantly, they observed that the combined
administration of a high-fat diet and dextran sulphate sodium
not only worsened steatohepatitis, but also induced a pro-
ﬁbrogenic response in the liver. All together these data
support the theory that disturbances in the homeostasis
between bacteria and host at the intestinal epithelial cell level
lead not only to altered intestinal barrier but may also
promote bacterial translocation from the gut into the portal
circulation, further inducing liver damage [87,115]. However,
the nature and type of translocated microbial components
remains to be studied. Lastly, growing evidence suggests that at
the early onset of a high-fat diet, not only bacterial products
but also complete living bacteria can be translocated from the
intestinal lumen towards tissues, such as the adipose tissue
[116,117], enhancing the role of bacterial translocation and gut
permeability in tissue injury. The accumulation of translocated
bacteria in the metabolically active tissues can also participate
in exacerbating hepatic inﬂammation and ﬁbrosis
Altered choline metabolism
Choline is an important phospholipid component of the cell
membrane, and a key partner of fat metabolism in the liver,
and of very-low-lipoprotein assembly. Lastly, it promotes lipid
transport from the liver [118]. A choline-deﬁcient diet
promotes liver steatosis, which is reversible by choline infusion
[119]. Enzymes produced by the gut microbiota catalyse the
conversion of dietary choline into toxic methylamines (dim-
ethylamine and trimethylamine). The uptake by the liver of
those amines and their transformation to trimethylamine-N-
oxide can induce liver inﬂammation [120,121]. Interestingly,
Spencer et al. showed that variations in levels of Gammapro-
teobacteria and Erysipelotrichi in human faecal microbiota
were directly associated with changes in liver fat during choline
depletion [122]. Hence, microbiota dysbiosis can promote
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NASH both by decreasing choline levels and increasing toxic
methylamines [123,124].
Modiﬁcation of bile acid metabolism
Representing the main components of bile, bile acids are
secreted into the duodenum and work to emulsify liposoluble
dietary nutrients to facilitate their digestion and absorption.
They also have a strong antimicrobial activity. Bile acids damage
bacterial cell membranes by interacting with membrane
phospholipids, which results in bactericidal activity [125].
Recent studies have demonstrated that dietary fats (high in
saturated fat), by promoting changes in host bile acid compo-
sition, can markedly alter conditions for gut microbial assem-
blage, resulting in dysbiosis [126,127]. Reciprocally, the gut
microbiota is able to modulate bile acid metabolism, through
farsenoid X receptor stimulation [89]. Dekaney et al. showed
that farnesoid X receptor (FXR) null and germ-free mice failed
to induce the expression of bile acid transport genes, following
ileo-caecal resection, compared with wild type mice [128].
Indeed, bile acids are ligands for a G-protein-coupled receptor
(TGR5/Gpbar-1) and activate nuclear receptors such as FXR
(NR1H4). FXR and its downstream targets play a key role in the
control of hepatic de novo lipogenesis, very-low-density
lipoprotein-triglyceride export and plasma triglyceride turn-
over [129], whereas TGR5 binds secondary bile acids and
promotes glucose homeostasis, by stimulating secretion of
glucagon-like peptide 1 [130]. Administration of speciﬁc TGR5
agonists lowers serum and liver triglyceride levels, thereby
reducing liver steatosis [131]. By modifying bile acid metabolism
and FXR/TGR5 signalling, gut ﬂora could therefore contribute
indirectly to the development of NAFLD [132].
Hepatotoxic microbial by-products: role of ethanol
Intestinal microﬂora produces a number of potentially hepa-
totoxic compounds such as ethanol, phenols, ammonia, which
are delivered to the liver by the portal circulation. Those
compounds activate Kupffer cells (resident hepatic macro-
phages) and stimulate their production of nitric oxide and
cytokines [88]. Acetaldehyde and acetate are two major
metabolites of ethanol. While acetate is a substrate for fatty
acid synthesis, acetaldehyde may lead to the production of
ROS. This could be involved in liver injury by contributing to
the disruption of intestinal barrier function and to the two-hit
mechanisms of NASH. Remarkably, Zhu et al. studied gut
microbiota of patients with and without NASH in obese
individuals and in healthy children. They observed an increase
of alcohol-producing bacteria in the gut microbiota of children
with NASH, associated with an elevated blood alcohol
concentration, without dietary alcohol consumption [133].
Furthermore, they reported that Escherichia (a well-known
ethanol producer [134]) stood out as the only abundant genus
that differed between NASH and obese patients without
NASH. Interestingly, changes in Enterobacteria seem to be a
frequent feature in obesity and weight changes. Importantly,
this endogenously produced alcohol has a well-established role
in the generation of ROS and consequently liver inﬂammation
[135]. Moreover, this could participate in the increase of gut
permeability [88,136,137].
Gut microbiota modulation as a new therapeutic strategy
Probiotics are deﬁned as live commensal microorganisms, that
when consumed in adequate quantities, confer a health beneﬁt
to the host (FAO/WHO 2001) [138]. Probiotics have been
suggested as a treatment to prevent chronic liver damage,
because they prevent bacterial translocation and epithelial
invasion, inhibit mucosal adherence by bacteria, produce
antimicrobial peptides, decrease inﬂammation and stimulate
host immunity [139,140]. The main probiotics on the market
are lactobacilli, streptococci and biﬁdobacteria [141]. Although
the literature on the subject is large, it is difﬁcult to draw
conclusions about the true effect of probiotics on NAFLD.
Indeed the animal models and bacterial strains tested across
the studies are different. Likewise, it must be noted that gut
microbiota will always outnumber the probiotics that can be
administered. Moreover, probiotic processes will always be
confounded by the variability of the human microbiome, diet
and genetics [142,143]. Several animal models have provided
evidence that probiotics may reduce NASH progression [144–
148]. The most studied probiotic is VSL#3 mixture, which was
ﬁrst given for 4 weeks in ob/ob mice fed with a high-fat diet
[144]. Treatment with VSL#3, improved liver histology,
reduced hepatic total fatty acid content, and decreased serum
alanine aminotransferase levels, a surrogate marker of NAFLD.
Ma et al. provided further evidence that VSL#3 ameliorates
insulin resistance and hepatic steatosis by preventing the
expected natural killer T-cell depletion induced by the high-fat
diet [145]. Several strains of lactobacillus have demonstrated a
protective effect on NAFLD [149–151], whereas a recent
meta-analysis pointed out the association of certain species
(L. fermentum and L. ingluviei) with weight gain [152]. Probiotics
have been shown to have several anti-inﬂammatory effects,
which could contribute to clinical beneﬁt in NAFLD, reviewed
elsewhere [88]. Regarding human studies, preliminary data
showed that both VSL#3 and a symbiotic (association of pro/
prebiotic) given to NAFLD patients for 2–3 months improved
liver enzymes, TNF-a and oxidative stress markers [153].
More recently, two randomized double-blind placebo-con-
trolled studies, showed a signiﬁcant decrease in liver amin-
otransferases with probiotics in children [154] and in adults
[155]. These promising results are strongly indicative of a great
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potential beneﬁt to use probiotics in the treatment of NAFLD.
Nonetheless, stated in a Cochrane meta-analysis, larger
randomized studies are still needed [156].
Prebiotics
Prebiotics are indigestible carbohydrates that stimulate the
growth and activity of beneﬁcial bacteria, particularly lactobacilli
and biﬁdobacteria [141]. Lactulose is a commonly used
prebiotic, which has proven its efﬁciency in reducing symptoms
in liver patients by increasing biﬁdobacteria [157]. Other
prebiotics include inulin-type fructans that can be differenti-
ated by their degree of polymerization such as long-chain and
short-chain, i.e. oligofructose and fructo-oligosaccharides
[158]. Several beneﬁcial effects of prebiotics on gut microbiota,
serum lipids and liver physiology have been shown [159].
Besides, in several animal models of NAFLD, lactulose and
oligo-fructose have been shown to reduce hepatic steatosis
development [160,161]. The potential mechanisms include
reduced de novo fatty acid synthesis, reduced body weight
through stimulation of gut peptides (glucagon-like peptide 1
and peptide YY), reduced inﬂammation and pro-inﬂammatory
cytokines (IL6, TNF-a), improved glycemic control, modula-
tion of gut microbiota and alterations in volatile organic
compounds [83,159]. Yet, studies assessing the effects of
prebiotics on NAFLD in humans are lacking. Nevertheless, a
pilot study already gives encouraging results, since Daubioul
et al. showed a reduction in liver enzymes and fasting
insulinaemia in seven patients with NASH who were treated
with oligo-fructose for 8 weeks [162].
Conclusion
Gut–liver axis plays a central role in the pathogenesis of
NAFLD, mainly through the crosstalk of the intestinal micro-
biota with the host immune system modulating inﬂammation,
insulin resistance and intestinal permeability. Large-scale
randomized trials using antibiotics, probiotics and prebiotics
with imaging and histological endpoints are needed.
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